Astrazeneca Plc ADR (AZN)
68.05 +1.01 (1.51%)
AstraZeneca is a global biopharmaceutical company that focuses on the research, development, and manufacturing of a wide range of prescription medications. The company's primary areas of expertise include oncology, respiratory diseases, cardiovascular systems, and immunology, with a commitment to advancing innovative treatments that improve patient outcomes. AstraZeneca collaborates with healthcare professionals, researchers, and academic institutions to drive scientific advancements and ensure that their therapies reach those in need. Through its extensive portfolio, the company aims to address some of the world’s most pressing health challenges while maintaining a strong emphasis on sustainability and corporate responsibility.
Previous Close | 67.04 |
---|---|
Open | 68.42 |
Bid | 68.06 |
Ask | 68.60 |
Day's Range | 68.00 - 68.65 |
52 Week Range | 60.47 - 87.68 |
Volume | 4,291,049 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 1.000 (1.47%) |
1 Month Average Volume | 8,224,305 |
News & Press Releases
The Law Offices of Frank R. Cruz Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) on behalf of investors concerning the Company’s possible violations of federal securities laws.
By The Law Offices of Frank R. Cruz · Via Business Wire · December 3, 2024
Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons'benzinga.com
Via Benzinga · December 3, 2024
Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines.
Via MarketBeat · November 28, 2024
TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC).
By AstraZeneca · Via Business Wire · November 25, 2024
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Nowfool.com
Via The Motley Fool · November 21, 2024
AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concernsbenzinga.com
FDA panel to discuss AstraZeneca's supplemental application for Andexxa amid safety concerns, including thrombosis risks and efficacy limitations.
Via Benzinga · November 21, 2024
This AstraZeneca Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesdaybenzinga.com
Via Benzinga · November 20, 2024
AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative to improve access, affordability and outcomes for patients in urban, suburban and rural communities. This brings the total contributions from the program to more than $15 million to date.
By AstraZeneca · Via Business Wire · November 20, 2024
Not-So-Big Pharmatalkmarkets.com
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration.
Via Talk Markets · November 16, 2024
European And US Vaccine Stocks Are Under Pressure - Here's WHybenzinga.com
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts.
Via Benzinga · November 15, 2024
Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending Itbenzinga.com
Altria Group is "undervalued," Cramer says. On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38.
Via Benzinga · November 15, 2024
WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhillbenzinga.com
Trump's decision to appoint Kennedy, known for his vaccine skepticism, has sparked significant attention.
Via Benzinga · November 15, 2024
Is AstraZeneca a Buy as It Eyes the Weight Loss Market?fool.com
Via The Motley Fool · November 14, 2024
Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lowerbenzinga.com
Trump may appoint Robert F. Kennedy Jr. as HHS Secretary, stirring mixed reactions. Kennedy's views on vaccines could reshape policies and affect vaccine stocks.
Via Benzinga · November 14, 2024
AstraZeneca Plc (AZN) Q3 2024 Earnings Call Transcriptfool.com
Via The Motley Fool · November 12, 2024
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Diseasebenzinga.com
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.
Via Benzinga · November 13, 2024
AstraZeneca Stock Dives As China's Criminal Probe Rattles Its Third-Quarter Beatinvestors.com
AstraZeneca Chief Executive Pascal Soriot said the company is taking the allegations "very seriously."
Via Investor's Business Daily · November 12, 2024
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'benzinga.com
AstraZeneca reports $13.57 billion in Q3 sales, up 18% year-over-year. Announces $3.5B U.S. investment to boost R&D and manufacturing with 1,000 new jobs.
Via Benzinga · November 12, 2024
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs contributing to the growth of the US economy.
By AstraZeneca · Via Business Wire · November 12, 2024
AstraZeneca’s 9M and Q3 2024 results
By AstraZeneca · Via Business Wire · November 12, 2024
The Week Kamala Harris Lost (Nov 4-8), These Large Cap Stocks Lost Bigbenzinga.com
Kamala Harris lost 2024 US election, 10 large-cap stocks performed poorly: Moderna, Honda, Akamai, ADS, AstraZeneca, Pinterest, MercadoLibre, First Solar, POSCO, Floor & Decor
Via Benzinga · November 11, 2024
AstraZeneca Q3 Earnings Preview: Will Cancer, Heart Drugs Fuel Continued Growth?benzinga.com
AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong growth driven by its oncology and cardiovascular portfolios.
Via Benzinga · November 11, 2024
AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitisbenzinga.com
AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.
Via Benzinga · November 8, 2024